- Trial Phase
- Phase 3
- Time to Market
- If Phase 3 NATiV3 succeeds in H2 2026, regulatory filing would follow, with potential FDA approval ~12-18 months later (late 2027 or early 2028).
- Why 8/10
- The single next hard, dated binary catalyst is the Phase 3 NATiV3 topline readout (expected Q4 2026, within ~3-6 months). Lanifibranor is Inventiva's only late-stage asset, making this a make-or-break event for a company whose equity value is almost entirely tied to this one drug. ImpactScore 8 reflects the binary nature and proximity of the readout.
Lanifibranor's Phase 3 NATiV3 topline readout (expected Q4 2026) is the most anticipated MASH catalyst of the year. The stock trades at ~$3.91 vs a mean analyst target of ~$15.13, reflecting the binary nature of the event. Monitor for any early interim data releases, DMC updates, or timeline changes. A positive readout could drive a multi-bagger re-rating; a failure would likely collapse the stock given Inventiva is a single-asset company.
Price Chart
Executive Summary
Lanifibranor is a pan-PPAR agonist oral drug in Phase 3 (NATiV3 trial) for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH), a chronic liver disease affecting millions. Inventiva is a single-asset biotech whose entire valuation hinges on this one readout — topline results are expected in Q4 2026. Phase 2b data (NEJM-published) showed statistically significant improvements in both MASH resolution and fibrosis reduction at 24 weeks, earning FDA Breakthrough Therapy designation. The MASH market is projected at $25-32B by 2032-33, and the only approved oral competitor is Madrigal's Rezdiffra (launched 2024, $350M H1 2025 sales). Analyst consensus is Strong Buy with a mean price target ~$15.13 (287% upside), but the stock's low price reflects real binary risk: a trial miss would be catastrophic.
How It Works
Lanifibranor is a daily oral pill that activates three related proteins in the body called PPARs (alpha, beta/delta, and gamma). These proteins act like metabolic master switches — together they reduce liver fat, fight inflammation, limit scar-tissue formation, and improve how the body processes sugar and fats. It's the first drug designed to hit all three PPAR targets at once, which gives it a broad approach to treating a complex liver disease.
Trial Status
The pivotal Phase 3 NATiV3 trial is fully enrolled (1,009 patients in the main cohort + 410 in exploratory cohort) and topline results are expected in Q4 2026 / H2 2026. The Data Monitoring Committee has given positive recommendations at all four scheduled meetings to continue without modification. Phase 2b NATIVE data was published in NEJM, showing 45% of patients achieving NASH resolution without worsening fibrosis at the 1,200 mg dose vs 19% placebo.
The Two-Sided Case
Upcoming Catalysts
- Phase 3 NATiV3 topline data readout (expected Q4 2026) — the single most important catalyst
- Potential additional interim DMC reviews or study updates
- EASL/AASLD conference presentations of additional NATiV3 substudy data
- Shareholder meeting outcomes and any capital structure updates
- CTTQ milestone payments (up to $265M in potential future milestones from China partnership)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Inventiva S.A. 6-K IVA ·Originating report